RenovoRx, Inc. (RNXT) 10-Year Financial Performance & Capital Metrics

RNXT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Show more

Revenue $43K
EBITDA -$11M +3.7%
Net Income -$9M +13.9%
EPS (Diluted) -0.37 +26.0%
Gross Margin 100%
EBITDA Margin -25511.63%
Operating Margin -25511.63%
Net Margin -20497.67%
ROE -1192.69% -84.3%
ROIC -
Debt/Equity 0.06
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 14.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM4.71%

ROCE

10Y Avg-227.05%

5Y Avg-217.33%

3Y Avg-261.06%

Latest-337.54%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	43K
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	43K
Gross Margin %	-	-	-	-	-	1%
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	3.9M	3.2M	5.67M	9.95M	11.4M	11.01M
OpEx % of Revenue	-	-	-	-	-	256.12%
Selling, General & Admin	899K	818K	2.63M	5.65M	5.73M	4.99M
SG&A % of Revenue	-	-	-	-	-	116%
Research & Development	3M	2.39M	3.04M	4.3M	5.67M	6.03M
R&D % of Revenue	-	-	-	-	-	140.12%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-3.9M	-3.2M	-5.67M	-9.95M	-11.4M	-10.97M
Operating Margin %	-	-	-	-	-	-255.12%
Operating Income Growth %	-	0.18%	-0.77%	-0.75%	-0.15%	0.04%
EBITDA+	-3.84M	0	-5.66M	-9.94M	-11.39M	-10.97M
EBITDA Margin %	-	-	-	-	-	-255.12%
EBITDA Growth %	-	1%	-	-0.76%	-0.15%	0.04%
D&A (Non-Cash Add-back)	0	3.2M	9K	6K	6K	0
EBIT	-3.84M	-3.2M	-5.49M	-9.95M	-11.4M	-10.97M
Net Interest Income+	63K	-587K	-834K	0	-108K	384K
Interest Income	63K	3K	0	57K	0	384K
Interest Expense	0	590K	834K	57K	108K	0
Other Income/Expense	57K	-594K	-653K	61K	1.16M	2.16M
Pretax Income+	-3.84M	-3.8M	-6.32M	-9.89M	-10.23M	-8.81M
Pretax Margin %	-	-	-	-	-	-204.98%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-3.84M	-3.8M	-6.32M	-9.89M	-10.23M	-8.81M
Net Margin %	-	-	-	-	-	-204.98%
Net Income Growth %	-	0.01%	-0.67%	-0.56%	-0.03%	0.14%
Net Income (Continuing)	-3.84M	-3.8M	-6.32M	-9.89M	-10.23M	-8.81M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.25	-0.40	-0.54	-0.50	-0.37
EPS Growth %	-	-0.14%	-0.6%	-0.35%	0.07%	0.26%
EPS (Basic)	-0.22	-0.25	-0.40	-0.54	-0.50	-0.37
Diluted Shares Outstanding	17.32M	17.32M	17.87M	18.1M	20.58M	23.61M
Basic Shares Outstanding	17.32M	17.32M	17.87M	18.1M	20.58M	23.61M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.27M	1.91M	16.28M	7.26M	1.47M	7.83M
Cash & Short-Term Investments	2.1M	1.79M	15.19M	6.44M	1.17M	7.15M
Cash Only	2.1M	1.79M	15.19M	4.39M	1.17M	7.15M
Short-Term Investments	0	0	0	2.05M	0	0
Accounts Receivable	0	0	0	0	0	43K
Days Sales Outstanding	-	-	-	-	-	365
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	20K	0	0	825K	101K	303K
Total Non-Current Assets+	4K	4K	6K	0	0	290K
Property, Plant & Equipment	0	0	6K	0	0	290K
Fixed Asset Turnover	-	-	-	-	-	0.15x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	4K	4K	0	0	0	0
Total Assets+	2.27M	1.91M	16.29M	7.26M	1.47M	8.12M
Asset Turnover	-	-	-	-	-	0.01x
Asset Growth %	-	-0.16%	7.51%	-0.55%	-0.8%	4.54%
Total Current Liabilities+	805K	4.1M	938K	1.1M	1.18M	1.91M
Accounts Payable	538K	162K	525K	534K	561K	586K
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	2.77M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	35K	895K	0	475K	75K	817K
Current Ratio	2.81x	0.47x	17.36x	6.59x	1.25x	4.10x
Quick Ratio	2.81x	0.47x	17.36x	6.59x	1.25x	4.10x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	12.47M	0	0	3.29M	1.73M
Long-Term Debt	0	23K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	212K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	12.45M	0	0	3.29M	1.52M
Total Liabilities	805K	16.57M	938K	1.1M	4.47M	3.64M
Total Debt+	0	2.79M	0	0	0	278K
Net Debt	-2.1M	995K	-15.19M	-4.39M	-1.17M	-6.88M
Debt / Equity	-	-	-	-	-	0.06x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-5.43x	-6.80x	-174.56x	-105.52x	-
Total Equity+	1.47M	-14.66M	15.35M	6.16M	-3M	4.48M
Equity Growth %	-	-11%	2.05%	-0.6%	-1.49%	2.49%
Book Value per Share	0.08	-0.85	0.86	0.34	-0.15	0.19
Total Shareholders' Equity	1.47M	-14.66M	15.35M	6.16M	-3M	4.48M
Common Stock	1K	1K	1K	1K	1K	2K
Retained Earnings	-11.16M	-14.96M	-21.28M	-31.17M	-41.41M	-50.22M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-16.29M	17K	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.35M	-3.53M	-5.92M	-8.81M	-10.26M	-9.13M
Operating CF Margin %	-	-	-	-	-	-212.21%
Operating CF Growth %	-	-0.05%	-0.68%	-0.49%	-0.16%	0.11%
Net Income	-3.84M	-3.8M	-6.32M	-9.89M	-10.23M	-8.81M
Depreciation & Amortization	0	0	9K	6K	0	0
Stock-Based Compensation	38K	0	147K	0	1.08M	1.17M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	8K	539K	517K	644K	-1.71M	-1.76M
Working Capital Changes	443K	-269K	-265K	428K	605K	280K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	343K	-376K	363K	9K	27K	25K
Cash from Investing+	-1K	0	-15K	-2.03M	2.03M	-12K
Capital Expenditures	0	0	-15K	0	0	-12K
CapEx % of Revenue	-	-	-	-	-	0.28%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-1K	0	0	0	0	0
Cash from Financing+	0	3.2M	19.33M	42K	5.01M	15.12M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	2.79M	0	8K	102K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-3.35M	-3.53M	-5.93M	-8.81M	-10.26M	-9.14M
FCF Margin %	-	-	-	-	-	-212.49%
FCF Growth %	-	-0.05%	-0.68%	-0.49%	-0.16%	0.11%
FCF per Share	-0.19	-0.20	-0.33	-0.49	-0.50	-0.39
FCF Conversion (FCF/Net Income)	0.87x	0.93x	0.94x	0.89x	1.00x	1.04x
Interest Paid	0	0	0	0	14K	21K
Taxes Paid	0	0	0	0	38K	2K

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-262.05%	-	-1825.11%	-91.94%	-646.98%	-1192.69%
Return on Invested Capital (ROIC)	-	-	-	-773.72%	-	-
Gross Margin	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-20497.67%
Debt / Equity	-	-	-	-	-	0.06x
Interest Coverage	-	-5.43x	-6.80x	-174.56x	-105.52x	-
FCF Conversion	0.87x	0.93x	0.94x	0.89x	1.00x	1.04x

Revenue by Segment

	2024
Other Operating	43K
Other Operating Growth	-

Frequently Asked Questions

Growth & Financials

RenovoRx, Inc. (RNXT) reported $0.9M in revenue for fiscal year 2024.

RenovoRx, Inc. (RNXT) grew revenue by 0.0% over the past year. Growth has been modest.

RenovoRx, Inc. (RNXT) reported a net loss of $11.1M for fiscal year 2024.

Dividend & Returns

RenovoRx, Inc. (RNXT) has a return on equity (ROE) of -1192.7%. Negative ROE indicates the company is unprofitable.

RenovoRx, Inc. (RNXT) had negative free cash flow of $10.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener